provide the corrections suggested on the document uploaded

1

4

Comment by Julie B: Hello, and thank you for using our service. To see my explanations, feedback, and resource links for your paper, please click on the link called "Feedback Form." I will highlight comments in yellow that are repeated concerns.

Concept Analysis Comment by Julie B: APA: Move this up a few lines, and skip only one line below it. Everything should be contained in the top half of the page.

Valeria Klimack Miami Regional University DNP 7000: Evolution of Nursing Practice Application of Theory in Nursing Practice Dr. Karen Perez 03/12/2025

Concept Analysis

Management of neuropathic pain is crucial in clinical management, particularly in lumbar radiculopathy, with chronic pain and impairment resulting from compression of the nerve root. The opioid crisis has prompted the shift away from opioid analgesics as the initial line of treatment. Treatment with gabapentin and pregabalin for lumbar radiculopathy will be the subject of this concept analysis. Walker and Avant's technique will describe and study these agents' key features, antecedents, consequences, and empirical referents for neuropathic pain treatment. This paper describes their clinical usage, recognizes their benefit over opioids, and outlines how to include them in evidence-based pain treatment strategies. Optimization of non-opioids for pain treatment with minimum patient damage is crucial in modern healthcare. Comment by Julie B: Do you mean “will be used to describe and study….”? Comment by Julie B: Avoid referring to your assignment like this. Clearly state the main argument and provide an outline of the paper’s structure to help guide the reader.

Name of the Concepts Chosen

Neuropathic pain therapy using gabapentin and pregabalin as opioid replacements for lumbar radiculopathy is the concept here. I chose this concept because of the growing recognition of the limitations and risks associated with opioid therapy including opioid therapy risks, including addiction, tolerance, and adverse effects. Gabapentinoids reduce neuronal excitability, neuropathic pain, and calcium channels without opioid dependency (Chincholkar, 2020). Opioid-sparing pain management may enhance patient outcomes and public health. According to Walker and Avant, recognizing this concept's antecedent, consequence, and empirical referents may enhance lumbar radiculopathy treatment evidence-based practice and clinical decision-making.

Concept Selected

Using gabapentin and pregabalin as opioid alternatives for lumbar radiculopathy therapy is the concept chosen for this investigation. This concept is critical given the opioid crisis and the need for safer, evidence-based pain management. Lumbar radiculopathy may impair function and quality of life due to nerve root compression and discomfort. Opioids were formerly the mainstay of treatment, but habit, tolerance, and adverse effects drove alternatives (Dey & Vrooman, 2022). Gabapentinoids reduce neuropathic pain without addiction by regulating calcium channels. As a healthcare practitioner committed to patient outcomes and harm reduction, this concept appeals to me. Understanding how antineuropathic medications manage pain affects clinical practice, prescriptions, and patient safety. Therapeutic uses must be appreciated when gabapentin's long-term benefits and downsides are studied. By analyzing this concept using Walker and Avant's method, I intend to promote responsible pain management and help the healthcare sector reduce opioid use. Gabapentinoids are beneficial for treating neuropathic pain, and this study will show their properties, causes, and consequences. Comment by Julie B: There is a lot of redundancy in the first two body paragraphs.

Aim of Analyzing the Concept

This concept analysis aims to identify and scientifically justify the use of gabapentin and pregabalin as opioid substitutes for lumbar radiculopathy. This study seeks to identify these medications' properties, causes, and therapeutic consequences. The change to opioid-sparing pain treatment requires a consistent conceptual framework for evidence-based nursing and healthcare policy. This approach can help nursing research by finding practice gaps, enhancing decision-making, and promoting safer pain care. A clear concept would enhance patient outcomes, eliminate opioid risks, and encourage gabapentinoids' long-term efficacy in treating neuropathic pain illnesses such as lumbar radiculopathy. Comment by Julie B: How does this analysis contribute to improving treatment decisions and pain management strategies.

Use of the Concept

In medical and nursing literature, the concept of treating neuropathic pain using antineuropathic drugs is well-established. Finnerup et al. (2021) define neuropathic pain as' pain caused by damage or disease affecting the somatosensory nervous system.' For neuropathic pain, gabapentinoids like pregabalin and gabapentin alter calcium channels and inhibit excitatory neurotransmitter release. These drugs are recommended first-line treatments for diabetic neuropathy, postherpetic neuralgia, and lumbar radiculopathy by the American Academy of Neurology (AAN) and the European Federation of Neurological Societies (EFNS). The fact that gabapentinoids are replacing opioids in healthcare, reducing reliance and overdose, is a testament to their growing evidence and relevance in pain therapy. Comment by Julie B: Provide more detail on how gabapentin and pregabalin are currently used in practice and their impact on treatment guidelines.

Attributes

The concept of treating neuropathic pain with antineuropathic drugs includes identifying characteristics. Gabapentin and pregabalin affect pain signals by targeting central nervous system calcium channels, not opioid receptors (Finnerup et al., 2021). Mechanism-specific activity is crucial. These drugs relieve pain and enhance function in lumbar radiculopathy, diabetic neuropathy, and postherpetic neuralgia. Prescriptions and overdose risks are reduced by opioid-sparing potential (Jalali et al., 2020). Since patient efficacy and acceptability vary, dose adjustments and monitoring for side effects such as dizziness and tiredness are needed. These traits define gabapentinoids for neuropathic pain. Comment by Julie B: How do the key characteristics of gabapentin and pregabalin differentiate them from opioids, and why do these features matter in pain management?

Antecedents

The concept of using antineuropathic drugs to treat neuropathic pain must go through several antecedents before being used in clinical practice. Before using gabapentinoids, neuropathic pain must be identified (Finnerup et al., 2021). NSAIDs and acetaminophen frequently fail or are contraindicated when gabapentin and pregabalin are used when inflammation is not the predominant cause of pain (Ghlichloo & Gerriets, 2023). A thorough pain examination, including patient history, pain characteristics, and functional impairment, must determine third, gabapentinoid therapeutic appropriateness. Informed consent and patient education ensure understanding of side effects, dosage, and pain reduction expectations. These antecedents are the foundation of effective antineuropathic pain treatment. Comment by Julie B: Is there a missing word or two here somewhere? Comment by Julie B: Provide more details on the evaluation process used before prescribing these medications.

Consequences

Consequences of neuropathic pain treatment with antineuropathic drugs include both favorable and bad results after gabapentin or pregabalin. A primary positive outcome is effective pain alleviation and better function since many lumbar radiculopathy patients enjoy decreased pain and improved mobility (Finnerup et al., 2021). Another benefit is decreased opioid dependency since gabapentinoids lessen addiction, overdose, and opioid-related side effects (Kopel & Brower, 2020). Potential negative consequences include dizziness, sedation, and cognitive impairment that might affect daily functioning, especially in elderly persons (Kopel & Brower, 2020). Long-term usage may cause abuse and dependence, necessitating patient monitoring. These consequences emphasize the necessity for tailored neuropathic pain management programs that balance pain alleviation with hazards to improve patient outcomes.

Empirical Referents

Empirical referents show neuropathic pain. A key referent is pain reduction scores, measured using the Numeric Pain Rating Scale (NPRS) or the Neuropathic Pain Scale (Finnerup et al.). The Oswestry Disability Index (ODI) measures lumbar radiculopathy patients' functional improvement. Gabapentinoids diminish opioid prescriptions and use (Sayed et al., 2022). Pharmacovigilance databases track drug abuse, dizziness, and sedation. Gabapentinoids treat neuropathic pain safely and effectively. Comment by Julie B: Missing year. Comment by Julie B: This paragraph reads like a list of ideas rather than a clear message. Make sure you start with a clear topic sentence and integrate your sources with analysis.

Conclusion Comment by Julie B: You do not need this heading.

Gabapentin and pregabalin were used in this concept analysis as opioid substitutes for lumbar radiculopathy. Mechanism-specific activity, neuropathic pain efficacy, opioid-sparing potential, and patient response heterogeneity are all central to this concept. Neuropathic pain, failure to respond to first-line analgesics for pain relief, pain assessment, and patient education are the prerequisites to treatment. They alleviate pain, lessen opioid addiction, have adverse effects, and misuse. Pain relief, function, opioid prescription rates, and adverse events measure clinical efficacy. This concept improves patient outcomes and decreases opioid risks using evidence-based pain treatment. This concept emphasizes gabapentinoids in pain treatment and clinical trials. Comment by Julie B: You have several sentences with this construction where you put the verb near the end. This is an awkward construction for an English sentence. Consider rearranging sentences like this to make “prerequisites” the subject with the verb right after it for a more direct statement. Comment by Julie B: Consider making a clearer link back to the thesis.

References

Bykov, K., Bateman, B. T., Franklin, J. M., Vine, S. M., & Patorno, E. (2020). Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. JAMA Network Open, 3(12), e2031647. https://doi.org/10.1001/jamanetworkopen.2020.31647 Comment by Julie B: There is no matching in-text citation for this source. Check all your references for this problem. Comment by Julie B: Use sentence case for the title of the source.

Chincholkar, M. (2020). Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. British Journal of Pain, 14(2), 104–114. https://doi.org/10.1177/2049463720912496

Dey, S., & Vrooman, B. M. (2022). Alternatives to Opioids for Managing Pain. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK574543/

Doneddu, P. E., Pensato, U., Iorfida, A., Alberti, C., Nobile‐Orazio, E., Fabbri, A., & Voza, A. (2023). Neuropathic pain in the emergency setting: Diagnosis and management. Journal of Clinical Medicine, 12(18), 6028–6028. https://doi.org/10.3390/jcm12186028 Comment by Julie B: Missing citation.

Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021). Neuropathic Pain: From Mechanisms to Treatment. Physiological Reviews, 101(1), 259–301. https://doi.org/10.1152/physrev.00045.2019

Ghlichloo, I., & Gerriets, V. (2023, May 1). Nonsteroidal Anti-inflammatory Drugs (NSAIDs). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK547742/

Jalali, M. S., Botticelli, M., Hwang, R. C., Koh, H. K., & McHugh, R. K. (2020). The opioid crisis: A contextual, social-ecological framework. Health Research Policy and Systems, 18(1), 1–9. https://doi.org/10.1186/s12961-020-00596-8

Kopel, J., & Brower, G. L. (2020). Effectiveness of pregabalin as a secondary treatment for neuropathic pain from postherpetic neuralgia. Baylor University Medical Center Proceedings, 33(3), 469–470. https://doi.org/10.1080/08998280.2020.1767461

Sayed, D., Grider, J., Strand, N., Hagedorn, J. M., Falowski, S., Lam, C. M., Tieppo Francio, V., Beall, D. P., Tomycz, N. D., Davanzo, J. R., Aiyer, R., Lee, D. W., Kalia, H., Sheen, S., Malinowski, M. N., Verdolin, M., Vodapally, S., Carayannopoulos, A., Jain, S., & Azeem, N. (2022). The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain. Journal of Pain Research, Volume 15, 3729–3832. https://doi.org/10.2147/jpr.s386879